GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (OTCPK:BRSYF) » Definitions » Cyclically Adjusted Price-to-FCF

BrainsWay (BrainsWay) Cyclically Adjusted Price-to-FCF : (As of May. 27, 2024)


View and export this data going back to 2012. Start your Free Trial

What is BrainsWay Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


BrainsWay Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BrainsWay's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay Cyclically Adjusted Price-to-FCF Chart

BrainsWay Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BrainsWay Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BrainsWay's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, BrainsWay's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrainsWay's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BrainsWay's Cyclically Adjusted Price-to-FCF falls into.



BrainsWay Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BrainsWay's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, BrainsWay's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.074/131.7762*131.7762
=0.074

Current CPI (Mar. 2024) = 131.7762.

BrainsWay Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.068 100.560 -0.089
201409 -0.121 100.428 -0.159
201412 -0.083 99.070 -0.110
201503 -0.188 99.621 -0.249
201506 -0.137 100.684 -0.179
201509 -0.083 100.392 -0.109
201512 -0.059 99.792 -0.078
201603 -0.024 100.470 -0.031
201606 -0.078 101.688 -0.101
201609 -0.017 101.861 -0.022
201612 -0.083 101.863 -0.107
201703 -0.123 102.862 -0.158
201706 -0.068 103.349 -0.087
201709 -0.051 104.136 -0.065
201712 -0.047 104.011 -0.060
201803 -0.063 105.290 -0.079
201806 -0.148 106.317 -0.183
201809 -0.053 106.507 -0.066
201812 -0.105 105.998 -0.131
201903 -0.075 107.251 -0.092
201906 -0.218 108.070 -0.266
201909 -0.148 108.329 -0.180
201912 -0.071 108.420 -0.086
202003 -0.154 108.902 -0.186
202006 -0.018 108.767 -0.022
202009 -0.073 109.815 -0.088
202012 0.079 109.897 0.095
202103 -0.025 111.754 -0.029
202106 -0.073 114.631 -0.084
202109 -0.019 115.734 -0.022
202112 0.070 117.630 0.078
202203 -0.075 121.301 -0.081
202206 -0.066 125.017 -0.070
202209 -0.066 125.227 -0.069
202212 -0.066 125.222 -0.069
202303 -0.102 127.348 -0.106
202306 -0.015 128.729 -0.015
202309 0.025 129.860 0.025
202312 0.062 129.419 0.063
202403 0.074 131.776 0.074

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BrainsWay  (OTCPK:BRSYF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BrainsWay Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BrainsWay's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BrainsWay (BrainsWay) Business Description

Traded in Other Exchanges
Address
19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.